NOS2 and cancer: MDSCs derived from various pathological conditions (such as cancer, inflammation and autoimmune diseases) can inhibit specific antitumor immunity mediated by T cells and natural antitumor immunity mediated by NK cells and macrophages by expressing high levels of ARG-1, INOS and ROS [5, 6].